GC Biopharma Corp. (KRX:006280)

Revenue by Product

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005	1988 - 2004
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	1988 - 2004
Manufacturing and Sales of Pharmaceuticals, etc.	1.58T																				Upgrade
Manufacturing and Sales of Pharmaceuticals, etc. Growth	9.72%																				Upgrade
Diagnosis and Analysis of Specimens, etc.	200.12B																				Upgrade
Diagnosis and Analysis of Specimens, etc. Growth	-6.38%																				Upgrade
Consolidation Adjustment, etc.	-117.27B																				Upgrade
Consolidation Adjustment, etc. Growth	152.23%																				Upgrade
Other	16.06B																				Upgrade
Other Growth	-13.17%																				Upgrade

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005	1988 - 2004
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	1988 - 2004
South Korea	1.42T																				Upgrade
South Korea Growth	1.16%																				Upgrade
Overseas	380.65B																				Upgrade
Overseas Growth	39.50%																				Upgrade
Consolidation Adjustment	-117.27B																				Upgrade
Consolidation Adjustment Growth	152.23%																				Upgrade